Impact of Baseline Best-Corrected Visual Acuity on Outcomes with Aflibercept 8 mg in Patients with Diabetic Macular Edema

Read full text Summarise with VIRAT
Authors: Michael Javaheri, Priya S. Vakharia, Talia R. Kaden, Sean D. Adrean, Philip J. Ferrone, Xiaomeng Niu, Jenfue Maa, Sharad Rastogi, Disha Patel, Hadi Moini, Kimberly Reed, Alyson J. Berliner
+1 more V. Diana
Cited by: 0
References: 5

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aflibercept 8 mg demonstrated comparable visual and anatomic improvements versus 2 mg in patients with diabetic macular edema at week 96, regardless of baseline best-corrected visual acuity ≤20/50 versus ≥20/40.

Fields of Study & Subjects

Retinal Diseases and Treatments Retinal and Macular Surgery Ocular Diseases and Behçet’s Syndrome

Publication details

Journal / source
Ophthalmology Retina
Volume
10
Issue
8
Pages
887–890
Publication date
30 March 2026
Language
EN